MedTrace Logo

Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

NCT02187029 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-11-11

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the effect of PF-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.

Conditions

Interventions

DRUG

PF-06743649

Daily dosing (dose level 1) tablet for 14 days

OTHER

Placebo

Daily dosing (tablet) for 14 days

DRUG

PF-06743649

Daily dosing (dose level 2) tablet(s) for 14 days

OTHER

Placebo

Daily dosing (tablets) for 14 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02187029 on ClinicalTrials.gov